lifitegrast 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
integrin antagonists	5174	1025967-78-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: lifitegrast SAR 1118-023 SAR 1118 SAR-1118 xiidra	a lymphocyte function-associated antigen-1 ( LFA-1) antagonist, blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1), LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues Molecular weight: 615.48 Formula: C29H24Cl2N2O7S CLOGP: 2.28 LIPINSKI: 1 HAC: 9 HDO: 2 TPSA: 133.99 ALOGS: -5.03 ROTB: 7 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

lifitegrast
SAR 1118-023
SAR 1118
SAR-1118
xiidra

a lymphocyte function-associated antigen-1 ( LFA-1) antagonist, blocks the interaction of LFA-1 with its cognate ligand intercellular adhesion molecule-1 (ICAM-1), LFA-1/ICAM-1 interaction can contribute to the formation of an immunological synapse resulting in T-cell activation and migration to target tissues

Molecular weight: 615.48
Formula: C29H24Cl2N2O7S
CLOGP: 2.28
LIPINSKI: 1
HAC: 9
HDO: 2
TPSA: 133.99
ALOGS: -5.03
ROTB: 7

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 11, 2016	FDA	SHIRE DEV LLC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Instillation site pain	2908.66	31.32	400	6985	504	63481133
Instillation site reaction	2281.73	31.32	300	7085	182	63481455
Eye irritation	1758.07	31.32	424	6961	21547	63460090
Vision blurred	1337.25	31.32	471	6914	91453	63390184
Dysgeusia	783.01	31.32	267	7118	46443	63435194
Instillation site irritation	594.15	31.32	78	7307	44	63481593
Instillation site pruritus	559.78	31.32	71	7314	14	63481623
Instillation site erythema	514.12	31.32	67	7318	32	63481605
Eye pain	487.29	31.32	173	7212	33681	63447956
Instillation site lacrimation	432.48	31.32	54	7331	3	63481634
Ocular hyperaemia	340.80	31.32	123	7262	25021	63456616
Lacrimation increased	294.87	31.32	105	7280	20526	63461111
Dry eye	279.90	31.32	122	7263	40639	63440998
Eye discharge	271.41	31.32	74	7311	5989	63475648
Instillation site discharge	260.52	31.32	33	7352	6	63481631
Instillation site swelling	217.65	31.32	27	7358	0	63481637
Product container issue	207.99	31.32	47	7338	1746	63479891
Eye pruritus	200.31	31.32	77	7308	18594	63463043
Product quality issue	169.81	31.32	83	7302	35782	63445855
Instillation site discomfort	169.28	31.32	21	7364	0	63481637
Ocular discomfort	149.81	31.32	43	7342	4190	63477447
Visual impairment	144.76	31.32	101	7284	84345	63397292
Product use complaint	138.22	31.32	36	7349	2438	63479199
Eye disorder	111.83	31.32	54	7331	22631	63459006
Instillation site dryness	101.30	31.32	13	7372	4	63481633
Eyelid margin crusting	91.96	31.32	22	7363	1050	63480587
Eye swelling	88.78	31.32	47	7338	23871	63457766
Instillation site inflammation	88.66	31.32	11	7374	0	63481637
Product packaging quantity issue	86.78	31.32	22	7363	1337	63480300
Foreign body sensation in eyes	84.91	31.32	24	7361	2210	63479427
Instillation site foreign body sensation	77.98	31.32	10	7375	3	63481634
Instillation site burn	72.54	31.32	9	7376	0	63481637
Taste disorder	71.81	31.32	34	7351	13628	63468009
Inappropriate schedule of product administration	68.79	31.32	72	7313	103893	63377744
Superficial injury of eye	66.43	31.32	13	7372	236	63481401
Instillation site hypersensitivity	56.42	31.32	7	7378	0	63481637
Product taste abnormal	55.65	31.32	17	7368	2050	63479587
Madarosis	48.99	31.32	17	7368	3064	63478573
Instillation site paraesthesia	48.36	31.32	6	7379	0	63481637
Product dose omission issue	47.46	31.32	92	7293	234221	63247416
Swelling of eyelid	44.78	31.32	16	7369	3140	63478497
Asthenopia	37.56	31.32	13	7372	2324	63479313
Erythema of eyelid	33.99	31.32	12	7373	2274	63479363
Product dispensing issue	33.83	31.32	7	7378	170	63481467
Product delivery mechanism issue	33.81	31.32	8	7377	364	63481273
Product storage error	33.07	31.32	21	7364	14935	63466702
Product packaging issue	32.81	31.32	10	7375	1196	63480441
Product label issue	32.75	31.32	9	7376	747	63480890
Photophobia	32.28	31.32	22	7363	17613	63464024
Instillation site haemorrhage	32.24	31.32	4	7381	0	63481637

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Instillation site reaction	607.32	98.13	67	1126	19	34955719
Vision blurred	545.29	98.13	150	1043	45813	34909925
Instillation site pain	509.57	98.13	58	1135	40	34955698
Eye irritation	458.47	98.13	93	1100	7468	34948270
Lacrimation increased	138.47	98.13	36	1157	8446	34947292
Instillation site lacrimation	130.08	98.13	14	1179	0	34955738
Eye pain	108.96	98.13	33	1160	13429	34942309
Instillation site erythema	98.78	98.13	11	1182	4	34955734

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Instillation site pain	2341.79	39.70	292	3752	431	79739913
Instillation site reaction	1837.58	39.70	218	3826	137	79740207
Vision blurred	821.95	39.70	275	3769	105623	79634721
Eye irritation	558.50	39.70	142	3902	20539	79719805
Instillation site irritation	421.91	39.70	50	3994	29	79740315
Instillation site erythema	416.35	39.70	49	3995	24	79740320
Dysgeusia	411.96	39.70	141	3903	57036	79683308
Instillation site pruritus	365.42	39.70	42	4002	9	79740335
Instillation site lacrimation	305.74	39.70	35	4009	6	79740338
Eye pain	192.01	39.70	72	3972	37506	79702838
Ocular hyperaemia	188.84	39.70	66	3978	28140	79712204
Instillation site swelling	186.73	39.70	21	4023	0	79740344
Eye discharge	160.32	39.70	41	4003	5993	79734351
Instillation site discomfort	160.05	39.70	18	4026	0	79740344
Instillation site discharge	160.05	39.70	18	4026	0	79740344
Product quality issue	155.22	39.70	60	3984	33880	79706464
Lacrimation increased	148.12	39.70	52	3992	22425	79717919
Product container issue	106.10	39.70	22	4022	1269	79739075
Eye pruritus	89.15	39.70	35	4009	20535	79719809
Instillation site burn	80.02	39.70	9	4035	0	79740344
Visual impairment	73.45	39.70	50	3994	92081	79648263
Instillation site inflammation	71.12	39.70	8	4036	0	79740344
Product dose omission issue	66.76	39.70	72	3972	247465	79492879
Instillation site foreign body sensation	62.23	39.70	7	4037	0	79740344
Eye swelling	58.49	39.70	28	4016	26440	79713904
Instillation site dryness	50.91	39.70	6	4038	3	79740341
Foreign body sensation in eyes	49.24	39.70	13	4031	2144	79738200
Inappropriate schedule of product administration	49.07	39.70	46	3998	133582	79606762
Product use complaint	47.43	39.70	13	4031	2470	79737874
Dry eye	47.00	39.70	27	4017	36904	79703440
Instillation site paraesthesia	44.45	39.70	5	4039	0	79740344
Ulcerative keratitis	42.34	39.70	13	4031	3676	79736668
Eyelid margin crusting	42.33	39.70	10	4034	1049	79739295
Eye disorder	40.57	39.70	21	4023	23391	79716953
Product packaging quantity issue	39.93	39.70	10	4034	1339	79739005

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	S01XA25	SENSORY ORGANS OPHTHALMOLOGICALS OTHER OPHTHALMOLOGICALS Other ophthalmologicals
MeSH PA	D009883	Ophthalmic Solutions
MeSH PA	D019999	Pharmaceutical Solutions
FDA MoA	N0000192700	Lymphocyte Function-Associated Antigen-1 Antagonists
FDA EPC	N0000192701	Lymphocyte Function-Associated Antigen-1 Antagonist
CHEBI has role	CHEBI:35472	anti-inflammatory drugs
CHEBI has role	CHEBI:133024	lymphocyte function-associated antigen-1 antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Tear film insufficiency	indication	46152009

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.42	acidic
pKa2	12.3	acidic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
5%	XIIDRA	NOVARTIS	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	10124000	Nov. 5, 2024	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5%	XIIDRA	NOVARTIS	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	7745460	Nov. 5, 2024	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5%	XIIDRA	NOVARTIS	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	7790743	Nov. 5, 2024	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5%	XIIDRA	NOVARTIS	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	8592450	May 17, 2026	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5%	XIIDRA	NOVARTIS	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	8367701	April 15, 2029	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5%	XIIDRA	NOVARTIS	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	9447077	April 15, 2029	TREATMENT OF THE SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)
5%	XIIDRA	NOVARTIS	N208073	July 11, 2016	RX	SOLUTION/DROPS	OPHTHALMIC	8168655	May 9, 2029	TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Integrin alpha-L/beta-2	Adhesion	P20701 P05107	ITAL_HUMAN ITB2_HUMAN	ANTAGONIST	IC50	8.05		SCIENTIFIC LITERATURE	DRUG LABEL
Intercellular adhesion molecule 1	Antibody	P05362	ICAM1_HUMAN		IC50	8.53		CHEMBL

External reference:

ID	Source
038E5L962W	UNII
D10374	KEGG_DRUG
4035938	VANDF
C3713860	UMLSCUI
CHEBI:133023	CHEBI
CHEMBL2048028	ChEMBL_ID
11965427	PUBCHEM_CID
DB11611	DRUGBANK_ID
CHEMBL2048409	ChEMBL_ID
9584	INN_ID
7533	IUPHAR_LIGAND_ID
1801820	RXNORM
243704	MMSL
31873	MMSL
016935	NDDF
720489009	SNOMEDCT_US
763569006	SNOMEDCT_US
C575157	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Xiidra	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0911	SOLUTION/ DROPS	50 mg	OPHTHALMIC	NDA	24 sections
Xiidra	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0911	SOLUTION/ DROPS	50 mg	OPHTHALMIC	NDA	24 sections
Xiidra	HUMAN PRESCRIPTION DRUG LABEL	1	0078-0911	SOLUTION/ DROPS	50 mg	OPHTHALMIC	NDA	24 sections
Xiidra	HUMAN PRESCRIPTION DRUG LABEL	1	54092-606	SOLUTION/ DROPS	50 mg	OPHTHALMIC	NDA	23 sections